메뉴 건너뛰기




Volumn 66, Issue 5, 2014, Pages 851-860

ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer

Author keywords

Active surveillance; Biopsy; Competing risk; Disease progression; ERG expression; Pathology; Prostate cancer; TMPRSS2 ERG

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; BIOLOGICAL MARKER; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN;

EID: 84907578628     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.02.058     Document Type: Article
Times cited : (76)

References (30)
  • 1
    • 17844402699 scopus 로고    scopus 로고
    • 20-year outcomes following conservative management of clinically localized prostate cancer
    • Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
    • (2005) JAMA , vol.293 , pp. 2095-2101
    • Albertsen, P.C.1    Hanley, J.A.2    Fine, J.3
  • 2
    • 79955705831 scopus 로고    scopus 로고
    • Radical prostatectomy versus watchful waiting in early prostate cancer
    • Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer.N Engl J Med 2011; 364:1708-17.
    • (2011) N Engl J Med , vol.364 , pp. 1708-1717
    • Bill-Axelson, A.1    Holmberg, L.2    Ruutu, M.3
  • 3
    • 84859630507 scopus 로고    scopus 로고
    • Active surveillance in prostate cancer: Patient selection and triggers for intervention
    • Lees K, Durve M, Parker C. Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr Opin Urol 2012; 22:210-5.
    • (2012) Curr Opin Urol , vol.22 , pp. 210-215
    • Lees, K.1    Durve, M.2    Parker, C.3
  • 4
    • 27344451557 scopus 로고    scopus 로고
    • Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    • Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
    • (2005) Science , vol.310 , pp. 644-648
    • Tomlins, S.A.1    Rhodes, D.R.2    Perner, S.3
  • 5
    • 34248510706 scopus 로고    scopus 로고
    • TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
    • Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
    • (2007) Oncogene , vol.26 , pp. 4596-4599
    • Demichelis, F.1    Fall, K.2    Perner, S.3
  • 6
    • 84877097685 scopus 로고    scopus 로고
    • Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the Canary Prostate Active Surveillance Study
    • Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013;19:2442-50.
    • (2013) Clin Cancer Res , vol.19 , pp. 2442-2450
    • Lin, D.W.1    Newcomb, L.F.2    Brown, E.C.3
  • 7
    • 84895065530 scopus 로고    scopus 로고
    • Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer
    • Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.
    • (2014) Eur Urol , vol.65 , pp. 534-542
    • Leyten, G.H.J.M.1    Hessels, D.2    Jannink, S.A.3
  • 8
    • 77954997528 scopus 로고    scopus 로고
    • Antibody-based detection of ERG rearrangement-positive prostate cancer
    • Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12: 590-8.
    • (2010) Neoplasia , vol.12 , pp. 590-598
    • Park, K.1    Tomlins, S.A.2    Mudaliar, K.M.3
  • 9
    • 84862080503 scopus 로고    scopus 로고
    • ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies
    • Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012;15:165-9.
    • (2012) Prostate Cancer Prostatic Dis , vol.15 , pp. 165-169
    • Braun, M.1    Goltz, D.2    Shaikhibrahim, Z.3
  • 10
    • 84856937557 scopus 로고    scopus 로고
    • Immunohistochemical pitfalls in prostate pathology
    • Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol 2012;43:313-24.
    • (2012) Hum Pathol , vol.43 , pp. 313-324
    • Brimo, F.1    Epstein, J.I.2
  • 11
    • 79959684555 scopus 로고    scopus 로고
    • The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies
    • Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011;35: 1062-8.
    • (2011) Am J Surg Pathol , vol.35 , pp. 1062-1068
    • Yaskiv, O.1    Zhang, X.2    Simmerman, K.3
  • 12
    • 84857781655 scopus 로고    scopus 로고
    • ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
    • Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012;25:471-9.
    • (2012) Mod Pathol , vol.25 , pp. 471-479
    • Hoogland, A.M.1    Jenster, G.2    Van Weerden, W.M.3
  • 13
    • 24144493035 scopus 로고    scopus 로고
    • The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma
    • Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
    • (2005) Am J Surg Pathol , vol.29 , pp. 1228-1242
    • Epstein, J.I.1    Allsbrook, W.C.2    Amin, M.B.3    Egevad, L.L.4
  • 14
    • 0000120995 scopus 로고
    • A class of K-sample tests for comparing the cumulative incidence of a competing risk
    • Gray JR. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
    • (1988) Ann Stat , vol.16 , pp. 1141-1154
    • Gray, J.R.1
  • 16
    • 84877614360 scopus 로고    scopus 로고
    • Estimating a timedependent concordance index for survival prediction models with covariate dependent censoring
    • Gerds TA, Kattan MW, Schumacher M, Yu C. Estimating a timedependent concordance index for survival prediction models with covariate dependent censoring. Stat Med 2013;32:2173-84.
    • (2013) Stat Med , vol.32 , pp. 2173-2184
    • Gerds, T.A.1    Kattan, M.W.2    Schumacher, M.3    Yu, C.4
  • 17
    • 84904070395 scopus 로고    scopus 로고
    • Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: The value of the pattern of surveillance biopsies
    • Cary KC, Cowan JE, Sanford M, et al. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 2014;66:337-42.
    • (2014) Eur Urol , vol.66 , pp. 337-342
    • Cary, K.C.1    Cowan, J.E.2    Sanford, M.3
  • 18
    • 83955162939 scopus 로고    scopus 로고
    • Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program
    • Bul M, van den Bergh RCN, Rannikko A, et al. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 2012;61:370-7.
    • (2012) Eur Urol , vol.61 , pp. 370-377
    • Bul, M.1    Van Den Bergh Rcn2    Rannikko, A.3
  • 19
    • 84862018113 scopus 로고    scopus 로고
    • Chemical castration and anti-androgens induce differential gene expression in prostate cancer
    • Lehmusvaara S, Erkkila T, Urbanucci A, et al. Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol 2012;227:336-45.
    • (2012) J Pathol , vol.227 , pp. 336-345
    • Lehmusvaara, S.1    Erkkila, T.2    Urbanucci, A.3
  • 20
    • 84873607610 scopus 로고    scopus 로고
    • Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
    • Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.
    • (2013) Cancer Cell , vol.23 , pp. 159-170
    • Weischenfeldt, J.1    Simon, R.2    Feuerbach, L.3
  • 21
    • 38049123346 scopus 로고    scopus 로고
    • Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
    • Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
    • (2008) Oncogene , vol.27 , pp. 253-263
    • Attard, G.1    Clark, J.2    Ambroisine, L.3
  • 22
    • 77951723424 scopus 로고    scopus 로고
    • Molecular sampling of prostate cancer: A dilemma for predicting disease progression
    • Sboner A, Demichelis F, Calza S, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8.
    • (2010) BMC Med Genomics , vol.3 , pp. 8
    • Sboner, A.1    Demichelis, F.2    Calza, S.3
  • 23
    • 84890126344 scopus 로고    scopus 로고
    • Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: Performance of secretion capacity and TMPRSS2:ERG models
    • Whelan C, Kawachi M, Smith DD, et al. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models. J Urol 2014;191:220-6.
    • (2014) J Urol , vol.191 , pp. 220-226
    • Whelan, C.1    Kawachi, M.2    Smith, D.D.3
  • 24
    • 84866172302 scopus 로고    scopus 로고
    • The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis
    • Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21:1497-509.
    • (2012) Cancer Epidemiol Biomarkers Prev , vol.21 , pp. 1497-1509
    • Pettersson, A.1    Graff, R.E.2    Bauer, S.R.3
  • 25
    • 80053078529 scopus 로고    scopus 로고
    • Common gene rearrangements in prostate cancer
    • Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011;29:3659-68.
    • (2011) J Clin Oncol , vol.29 , pp. 3659-3668
    • Rubin, M.A.1    Maher, C.A.2    Chinnaiyan, A.M.3
  • 26
    • 78651284982 scopus 로고    scopus 로고
    • Role of prostate specific antigen andimmediate confirmatory biopsy inpredicting progression during active surveillance for low risk prostate cancer
    • AdamyA, Yee DS, Matsushita K, et al. Role of prostate specific antigen andimmediate confirmatory biopsy inpredicting progression during active surveillance for low risk prostate cancer. J Urol 2011;185: 477-82.
    • (2011) J Urol , vol.185 , pp. 477-482
    • Adamy, A.1    Yee, D.S.2    Matsushita, K.3
  • 27
    • 84868563896 scopus 로고    scopus 로고
    • Active surveillance for prostate cancer: A systematic review of the literature
    • Dallera MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
    • (2012) Eur Urol , vol.62 , pp. 976-983
    • Dallera, M.A.1    Albertsen, P.C.2    Bangma, C.3
  • 28
    • 84902344693 scopus 로고    scopus 로고
    • PSA doubling time as a progression criterion in an active surveillance programme for patients with localised prostate cancer
    • Thomsen FB, Christensen IJ, Brasso K, Roder MA, Iversen P. PSA doubling time as a progression criterion in an active surveillance programme for patients with localised prostate cancer. BJU Int 2014;113:E98-105.
    • (2014) BJU Int , vol.113 , pp. E98-E105
    • Thomsen, F.B.1    Christensen, I.J.2    Brasso, K.3    Ma, R.4    Iversen, P.5
  • 29
    • 73949130115 scopus 로고    scopus 로고
    • Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
    • Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28: 126-31.
    • (2010) J Clin Oncol , vol.28 , pp. 126-131
    • Klotz, L.1    Zhang, L.2    Lam, A.3    Nam, R.4    Mamedov, A.5    Loblaw, A.6
  • 30
    • 77956396162 scopus 로고    scopus 로고
    • Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program
    • Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-6.
    • (2010) J Clin Oncol , vol.28 , pp. 2810-2816
    • Ross, A.E.1    Loeb, S.2    Landis, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.